An Open-Label, Sequential Treatment Study to Assess the Single and Multiple Dose Pharmacokinetics of a New Tapentadol Prolonged-Release 250 mg Formulation in Healthy Subjects
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain; Pain
- Focus Pharmacokinetics
- 19 Jun 2013 New trial record